Table 1.
Baseline characteristics of inpatients with heart failure at Inselspital, 2015–2019
| No diabetes | Type 2 diabetes | |
|---|---|---|
| n (%) | 7728 (73%) | 2804 (27%) |
| Sex (% males) | 4468 (58%) | 1846 (66%) |
| Age in years, median [IQR] | 77.8 [67.6, 85.5] | 75.2 [67.5, 82.0] |
| BMIa in kg/m2, median [IQR] | 25.6 [22.6, 29.1] | 27.5 [24.2, 31.3] |
| Medical history | ||
| Chronic kidney disease | 2766 (36%) | 1636 (58%) |
| ASCVD | 3066 (40%) | 1384 (49%) |
| Hypertension | 3817 (49%) | 1980 (71%) |
| Atrial fibrillation | 2306 (30%) | 1053 (38%) |
| Dyslipidaemia | 108 (1%) | 106 (4%) |
| COPD | 726 (8%) | 250 (14%) |
| Medications | ||
| Insulin | 2263 (81%) | |
| Oral antidiabetic medications | 1506 (54%) | |
| Antithrombotic medications | 6987 (90%) | 2755 (98%) |
| Digoxins and nitrates | 1851 (24%) | 1049 (37%) |
| Diuretics | 6075 (79%) | 2658 (95%) |
| Beta-blockers | 5779 (75%) | 2356 (84%) |
| RAAS inhibitorsb | 5913 (77%) | 2451 (87%) |
| Ejection fraction, % median [IQR] | 45 [32, 60] | 45 [35, 60] |
| HFpEF % | 4512 (58%) | 1636 (58%) |
| HFrEF % | 3216 (42%) | 1168 (42%) |
| Deaths | 3770 (49%) | 1577 (56%) |
a summary estimates based on non-missing values (only 6,740 or 64% of patients have had BMI measurements)
b includes ACEi, aliskiren, ARB, ARNI
ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, ARNI angiotensin receptor-neprilysin inhibitor, ASCVD atherosclerotic cardiovascular disease, BMI body mass index; COPD chronic obstructive pulmonary disease, RAAS renin–angiotensin–aldosterone system